NervGen announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Read the full release: . #SCI #SpinalCordInjury #news.

“We achieved our primary endpoint demonstrating improved hand-motor connectivity and showed positive improvement in hand function in the chronic cohort of our Phase 1b/2a trial,” said Mike Kelly, NervGen’s President and Chief Executive Officer. Chief Medical Officer, Dr. Daniel.

NervGen announced the results from the chronic cohort (1-10 years post-injury) of its Phase 1b/2a clinical trial evaluating NVG-291 in spinal cord injury. Read more about the results: #SCI #SpinalCordInjury #news

#DYK: NervGen and Shirley Ryan AbilityLab are conducting a clinical trial in #SCI. Watch to learn more about our unique trial design using electrophysiology. . #spinalcordinjury #clinicaltrial #science

Learn more about our science: #spinalcordinjury #clinicaltrial #science.

At NervGen, we are working to change that. Our lead drug candidate, NVG-291, is a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair.

#DYK that spinal cord injury (#SCI) affects over 300,000 people in the U.S. and there are currently no approved drugs to enable sustained functional recovery?. A thread 🧵

NervGen Chief Medical Officer Dr. Daniel Mikol will present at the upcoming @ASIA_spine 2025 Annual Scientific Meeting. Learn more: #SCI #clinicaltrial #ASIA2025SCIAnnualMeeting

“This is a tough lifestyle.” - @ruffoloj, Board Member. #DYK there are approx. 18K new #spinalcordinjury cases each year in the U.S.? Learn how we are dedicated to developing neurorestorative therapeutics potentially helping those living with #SCI:

#NEWS: Today, we reported our Q1 2025 financial results and operational updates. Learn more: $NGEN $NGENF #SCI

NervGen announced the results of its Annual General Meeting of Shareholders that was held on May 6, 2025. Read the full release: #Shareholders #announcement #SCI

#Investors: Our President & CEO Mike Kelly will be discussing our work and clinical trial in spinal cord injury at the Bloom Burton & Co. Healthcare Investor Conference. We look forward to connecting on May 5 in Toronto. Learn more: #BBHIC2025 $NGENF

RT @LifeSciAdvisors: ICYMI: @Nervgen $NGEN $NGENF hosted a virtual investor event with Dr. Perez and Dr. Kirshblum to discuss the unmet med….

NervGen reports its 2024 year-end financial results and provides business updates. Read the full release here:

NervGen initiates expanded access policy to allow treatment use of NVG-291 for individuals who’ve participated in NervGen SCI clinical trials & meet specific eligibility criteria after FDA informs expanded access protocol for NVG-291 may proceed. #news

RT @LifeSciAdvisors: Join @NervgenP $NGEN $NGENF management for a virtual investor event on Apr. 9 at 10:00am ET with Drs. Monica Perez & S….

In @TheScientistLLC Innovation Spotlight, NervGen’s President & CEO, Mike Kelly, discusses the need for #SCI research, the challenges of nervous system repair, and how our lead drug candidate, NVG-291, aims to break barriers in spinal cord injury treatment.

In @TheScientistLLC Innovation Spotlight, NervGen’s President & CEO, Mike Kelly, discusses the need for #SCI research, the challenges of nervous system repair, and how our lead drug candidate, NVG-291, aims to break barriers in spinal cord injury treatment.